Halozyme (HALO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$110.19-0.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HALO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 1,663.7 | 1,396.6 | 1,015.3 | 829.3 | 660.1 | 443.3 | 267.6 | 196.0 | 151.9 | 316.6 | 146.7 | 135.1 | 75.3 | 54.8 | 42.3 | 56.1 |
| Total Revenues | — | — | — | — | — | — | — | — | 151.9 | 316.6 | 146.7 | 135.1 | 75.3 | 54.8 | 42.3 | 56.1 |
| Cost of Revenues | 292.4 | 228.8 | 159.4 | 192.4 | 139.3 | 81.4 | 43.4 | 45.5 | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 238.0 | 207.1 | 154.3 | 149.2 | 143.5 | 50.3 | 45.7 | 77.3 | 60.8 | 53.8 | 45.9 | 40.0 | 35.9 | 32.3 | 24.8 | 18.1 |
| R&D Expenses | — | — | 79.0 | 76.4 | 66.6 | 35.7 | 34.2 | 140.8 | 150.3 | 150.6 | 150.8 | 93.2 | 79.7 | 96.6 | 70.0 | 57.6 |
| Operating Income | 597.2 | 469.0 | 551.5 | 337.6 | 267.5 | 275.9 | 144.3 | (67.6) | (69.3) | 81.0 | (83.2) | (27.5) | (63.0) | (80.4) | (53.6) | (19.8) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 18.1 | 18.1 | 18.8 | 16.9 | 7.5 | 20.4 | 11.6 | 18.0 | 22.0 | 20.0 | 5.2 | 5.6 | 3.3 | — | — |
| EBT, Incl. Unusual Items | 583.3 | 466.9 | 557.1 | 348.3 | 248.9 | 248.5 | 129.3 | (72.3) | (79.8) | 61.6 | (101.9) | — | — | — | — | — |
| Income Tax Expense | 169.7 | 150.0 | 113.0 | 66.7 | 46.8 | (154.2) | 0.2 | (0.0) | 0.5 | (1.4) | 1.2 | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | 413.6 | 316.9 | 444.1 | 281.6 | 202.1 | 402.7 | 129.1 | (72.2) | (80.3) | 63.0 | (103.0) | (32.2) | (68.4) | (83.5) | (53.6) | (19.8) |
| Per Share | ||||||||||||||||
| Basic EPS | 3.53 | 2.64 | 3.50 | 2.13 | 1.48 | 2.86 | 0.95 | 0.46 | (0.56) | 0.46 | — | — | — | — | — | — |
| Diluted EPS | 3.41 | 2.56 | 3.43 | 2.10 | 1.44 | 2.74 | 0.91 | (0.50) | (0.56) | 0.45 | — | — | — | — | — | — |
| Revenue per Share | 13.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 117.3 | 119.8 | 126.8 | 131.9 | 136.8 | 140.6 | 136.2 | 144.3 | 143.6 | 136.4 | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 121.2 | 123.9 | 129.4 | 134.2 | 140.6 | 146.8 | 141.5 | 144.3 | 143.6 | 139.1 | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | 480.4 | 561.7 | 348.7 | 274.0 | 278.9 | 147.5 | (63.5) | (66.9) | 83.2 | (80.8) | (25.8) | (61.3) | (79.2) | (52.5) | (18.7) |
| EBIT | 597.2 | 469.0 | 551.5 | 337.6 | 267.5 | 275.9 | 144.3 | (67.6) | (69.3) | 81.0 | (83.2) | (27.5) | (63.0) | (80.4) | (53.6) | (19.8) |
| Effective Tax Rate | 29.1% | — | — | 19.2% | 18.8% | -62.0% | 0.2% | 0.0% | -0.7% | -2.2% | -1.1% | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.